Assembly Bio，Arbutus Bio开始在乙型肝炎中进行三联疗法的试验 20

StephenW

Assembly Bio, Arbutus Bio commence trial of triple combo therapy in hepatitis B
Feb. 26, 2021 7:52 AM ETAssembly Biosciences, Inc. (ASMB)By: Mamta Mayani, SA News Editor

    Assembly Biosciences (NASDAQ:ASMB) and Arbutus Biopharma (NASDAQ:ABUS) have initiated a Phase 2 clinical trial of Assembly Bio’s investigational capsid inhibitor, vebicorvir (VBR), in combination with Arbutus’ GalNAc delivered RNAi therapeutic candidate, AB-729, and standard-of-care nucleos(t)ide reverse transcriptase inhibitor (NrtI) therapy for the treatment of chronic HBV infection.
    The Phase 2 trial will evaluate the safety, pharmacokinetics, and antiviral activity of the triple combination of VBR, AB-729 and an NrtI compared to the double combinations of VBR with an NrtI and AB-729 with an NrtI.
    Approx. 60 patients with HBeAg negative chronic HBV are expected to be enrolled across these three treatment arms.
    The primary objective is to evaluate the safety and tolerability of the triple combination, while secondary objectives include to evaluate reduction in HBV viral biomarkers such as HBV DNA, HBV pgRNA and HBsAg.
    The companies initially collaborated in August 2020.
    ASMB is down 5% whereas ABUS gains 4.7% premarket.

StephenW

Assembly Bio，Arbutus Bio开始在乙型肝炎中进行三联疗法的试验
2021年2月26日，上午7:52 ETAssembly Biosciences，Inc.（ASMB）由：Mamta Mayani，SA新闻编辑

    Assembly Biosciences（NASDAQ：ASMB）和Arbutus Biopharma（NASDAQ：ABUS）已启动Assembly Bio研究性衣壳抑制剂vebicorvir（VBR）与Arbutus的GalNAc交付的RNAi治疗候选药物AB-729的2期临床试验，以及慢性乙肝病毒感染的护理标准核苷酸（t）逆转录酶抑制剂（NrtI）治疗。
    2期试验将评估VBR，AB-729和NrtI的三联组合与VBR和NrtI和AB-729和NrtI的双联组合相比的安全性，药代动力学和抗病毒活性。
    大约预计将在这三个治疗方案中招募60例HBeAg阴性慢性HBV患者。
    主要目标是评估三联组合的安全性和耐受性，而次要目标包括评估HBV病毒生物标志物（例如HBV DNA，HBV pgRNA和HBsAg）的减少。
    两家公司最初于2020年8月进行合作。
    ASMB下跌5％，而ABUS盘前上涨4.7％。

齐欢畅